BioCryst Pharmaceuticals Acquires Astria Pharmaceuticals Today, January 23, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) announced it completed acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company’s long-term growth trajectory. BioCryst adds navenibart BioCryst, a late-stage, long . . . This content is for paid subscribers. Please click here to …